RxDoctor Payments Data

Joshua Crase, PA

Physician Assistant · New Albany, INNPI 1235789421

Payments from drug & device makers

$2,235in general payments, 2019–2025

Across 91 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$530
  • Biohaven Pharmaceutical Holding Company Ltd.$368
  • AbbVie$340
  • AstraZeneca$253
  • Exact Sciences$250
  • Phathom Pharmaceuticals, Inc.$170
  • plus $324 from 8 others

What the payments were for

  • Food & beverage$2,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,235 in reported general payments places this provider in the 85th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$71,153
Medicare patients
276
Services billed
2,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$60,493
EliquisApixaban40$45,618
MounjaroTirzepatide39$42,569
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$28,504
FarxigaDapagliflozin Propanediol28$26,244
TrulicityDulaglutide18$20,951
JardianceEmpagliflozin13$19,489
LinzessLinaclotide27$14,304
Janumet XrSitagliptin Phos/Metformin Hcl13$13,270
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,713
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$7,525
XareltoRivaroxaban13$6,828
Ondansetron Hcl26$5,994
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen191$5,571
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$13$63,52057 claims
Novo NordiskOzempic$13$60,49340 claims
PfizerEliquis$13$45,61840 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$103$39,50368 claims
AstraZenecaFarxiga$253$26,24428 claims
Boehringer IngelheimJardiance$25$19,48913 claims
AbbVieLinzess$340$14,30427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →